A proper initial assessment of catheter occlusion is the key to successful management. The assessment screens are for both thrombotic and nonthrombotic causes (including mechanical occlusion). If mechanical occlusion is excluded, thrombotic occlusion is treated with alteplase. Nonthrombotic occlusions are treated according to their primary etiologies: lipid occlusion is treated with 70% ethanol, mineral precipitates are treated with 0.1-N hydrochloric acid (HCl), drug precipitates are treated according to their pH—acidic drugs can be cleared with 0.1-N HCl, basic medications can be cleared with sodium bicarbonate or 0.1-N sodium hydroxide (NaOH). Prevention of occlusion of central venous access devices is also critical. To date, no data conclusively show heparin flushes to be superior to saline flushes. No prophylactic regimen, including low-dose warfarin, low-molecular-weight heparin, or 1 unit heparin/mL of parenteral nutrition has been endorsed by any major medical, nursing, or pharmacy group due to lack of scientific evidence. The most encouraging information on decreasing occlusion rate comes from experience with positive-pressure devices that attach to the hub of most catheter lumens and prevent retrograde blood flow and, consequently, decrease the risk of thrombus formation in the catheter lumen. (Journal of Parenteral and Enteral Nutrition 30:S73-S81, 2006)
Get full access to this article
View all access options for this article.
References
1.
1. Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion?JPEN J Parenter Enteral Nutr.1995;19:75–79.
2.
2. Howard L, Ashley C. Management of complications in patients receiving home parenteral nutrition. Gastroenterology.2003;124:1651–1661.
3.
3. Moureau N, Poole S, Murdock MA, Gray SM, Semba CP. Central venous catheters in home infusion care: outcomes analysis in 50,470 patients. J Vasc Interv Radiol.2002;13:1009–1016.
4.
4. Gorski LA. Central venous access device occlusions, part 1: thrombotic causes and treatment. Home Healthc Nurse.2003;21:115–121.
5.
5. Wise M, Richardson D, Lum P. Catheter tip position: a sign of things to come. J Vasc Access Devices.2001;6:18–26.
6.
6. Grant J. Recognition, prevention, and treatment of home total parenteral nutrition central venous access complications. JPEN J Parenter Enteral Nutr.2002;26(suppl):S21–S28.
7.
7. National Institutes of Health, Drug Information Service. Management of central venous catheter occlusions. Available at: http: //www.cc.nih.gov/phar/updates/99nov-dec.html.
8.
8. Gorski LA, Czaplewski LM. Peripherally inserted central catheters. Home Healthc Nurse.2004;22:758–773.
9.
9. Herbst SL, Kaplan LK, McKinnon BT. Vascular access devices: managing occlusions and related complications in home infusion. Infusion.1998;4(suppl):S1–S32.
10.
10. Haire WD, Herbst SL. Use of alteplase (t-PA) for the management of thrombotic catheter dysfunction: guidelines from a consensus conference of the National Association of Vascular Access Networks (NAVAN). Nutr Clin Pract.2000;15:265–275.
11.
11. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter thrombosis in intensive care patients: incidence, risk factors, and relationship with catheter-related sepsis. Chest.1998;114:207–213.
12.
12. US Food and Drug Administration Med Watch. Important safety information letter: dear hospital pharmacy and physician [AstraZeneca, Inc. website]. Available at: http://www.fda. gov/med watch/safety/1999/strept.htm.
13.
13. Haire WD, Atkinson JB, Stephens LC. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost.1994;71:543–547.
14.
14. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER, for the COOLInvestigators. Recombinant tissue plasminogen activator (Alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial- the Cardiovascular thrombolytic to Open Occluded Lines (COOL) Efficacy Trial. J Vasc Interv Radiol.2001;12:951–955.
15.
15. Deitcher SR, Fesen MR, Kiproff PM, et al, for the COOL-2 Investigators,. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the Cardiovascular thrombolytic to Open Occluded Lines Trial. J Clin Oncol.2001;20:317–324.
16.
16. Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey ER, for the COOL investigators. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. J Vasc Interv Radiol.2002;13:1199–1205.
17.
17. Shen V, Li X, Murdock M, Resnansky L, McCluskey ER, Semba CP, for the COOLInvestigators. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol.2003;25:38–45.
18.
18. Jacobs BR, Haygood M, Hingl J. Recombinant tissue plasmino-gen activator in the treatment of central venous catheter occlusion in children. J Pediatr.2001;139:593–596.
19.
19. Fisher AA, Deffenbaugh C, Poole RL, Garcia M, Kerner JA Jr. The use of alteplase for restoring patency to occluded central venous access devices in infants and children. J Infus Nurs.2004;27:171–174.
20.
20. Choi M, Massicotte P, Marzinotto V, Chan AKC, Holmes JL, Andrew M. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr.2001;139:152–156.
21.
21. Chesler L, Feusner JH. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters. J Pediatr Hematol Oncol.2002;24:653–656.
22.
22. Svoboda P, Barton P, Barbarash OL, et al. Recombinant uroki-nase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center international trial. Crit Care Med.2004;32:1990–1996.
23.
23. Haire WD, Deitcher SR, Mullane KM, et al. Recombinant uroki-nase for restoration of patency in occluded central venous access devices: a double-blind placebo controlled trial. Thromb Hae-most.2004;92:575–582.
24.
24. Horne MK III. Thrombolytics for occluded catheters. Crit Care Med.2004;32:2146–2147.
25.
25. Owens LD. Reteplase for clearance of occluded venous catheters. Am J Health Syst Pharm.2002;59:1638–1640.
26.
26. Terrill KR, Lemons RS, Goldsby RE. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer. J Pediatr Hematol Oncol.2003;25:864–867.
27.
27. Liu CY, Jain V, Shields AF, Heilbrun LK. Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer. J Vasc Interv Radiol.2004;15:39–44.
28.
28. Pennington CR, Pithie AD. Ethanol lock in the management of catheter occlusion. JPEN J Parenter Enteral Nutr.1987;11:507–508.
30. Erdman SH, McElwee CL, Kramer JM, Zuppan CW, White JJ, Grill BB. Central line occlusion with three-in-one nutrition admixtures administered at home. JPEN J Parenter Enteral Nutr1994;18:177–181.
31.
31. Werlin SL, Lausten T, Jessen S, et al. Treatment of central venous catheter occlusions with ethanol and hydrochloric acid. JPEN J Parenter Enteral Nutr.1995;19:416–418.
32.
32. ter Borg F, Timmer J, de Kam SS, Sauerwein HP. Use of sodium hydroxide to clear partially occluded vascular access ports. JPEN J Parenter Enteral Nutr.1993;17:289–291.
33.
33. Garcia MG, Poole RL, Rubin GD, Kerner JA Jr. Successful use of repeated ethanol injections to clear a central venous catheter occlusion after urokinase failure. J Pediatr Pharm Pract.1999;4:152–156.
34.
34. Dannenberg C, Bierbach U, Rothe A, Beer J, Korholz D. Ethanol-lock technique in the treatment of bloodstream infection in pediatric oncology patients with Broviac catheter. J Pediatr Hematol Oncol.2003;25:616–621.
35.
35. Metcalf SCL, Chambers ST, Pithie AD. Use of ethanol locks to prevent recurrent line sepsis. J Infect.2004;49:20–22.
36.
36. Shulman RJ, Reed T, Pitre D, Laine L. Use of hydrochloric acid to clear obstructed central venous catheters. JPEN J Parenter Enteral Nutr.1988;12:509–510.
37.
37. Breaux CW Jr, Duke D, Georgeson KE, Mestre JR. Calcium phosphate crystal occlusion of central venous catheters used for total parenteral nutrition in infants and children: presentation and treatment. J Pediatr Surg.1987;9:829–832.
38.
38. Duffy LF, Kerzner B, Gebus V. Treatment of central venous catheter occlusions with hydrochloric acid. J Pediatr.1989;114:1002–1004.
39.
39. Testerman EJ. Restoring patency of central venous catheters obstructed by mineral precipitation using hydrochloric acid. J Vasc Nurs.1991;1:22.
40.
40. Holcombe BJ, Forloines-Lynn S, Garmhausen LW. Restoring patency of long-term central venous access devices. J Intraven Nurs.1992;15:36–41.
41.
41. Barbaric D, Curtin J, Pearson L, Shaw PJ. Role of hydrochloric acid in the treatment of central venous catheter infections in children with cancer. Cancer.2004;101:1866–1872.
42.
42. Reed T, Phillips S. Management of central venous catheter occlusions and repairs. J Intraven Nurs.1996;19:289–294.
43.
43. Harris JL, Maguire D. Developing a protocol to prevent and treat central venous catheter occlusions. J Intraven Nurs.1999;22:194–198.
45. Rummel MA, Donnelly PJ, Fortenbaugh CC. Clinical evaluation of a positive pressure device to prevent central venous catheter occlusions: results of a pilot study. Clin J Oncol Nurs.2001;5:261–265.
46.
46. LeDuc K. Efficacy of normal saline solution versus heparin solution for maintaining patency of peripheral intravenous catheters in children. J Emerg Nurs.1997;23:306–309.
47.
47. Stephens LC, Haire WD, Tarantolo S, et al. Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC). Transfus Sci.1997;18:187–193.
48.
48. Kamala F, Boo NY, Cheah FC, Birinder K. Randomized controlled trial of heparin for prevention of blockage of peripherally inserted central catheters in neonates. Acta Paediatr.2002;91:1350–1356.
49.
49. Randolf AG, Cook DJ, Gonzales CA, Andrew M. Benefit of hep-arin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest.1998;113:165–171.
50.
50. Krafte-Jacobs B, Sivit CJ, Mejia R, Pollack MM. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. J Pediatr.1995;126:50–54.
51.
51. Laster JL, Nichols WK, Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies. Arch Intern Med.1989;149:2285–2287.
52.
52. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med.1990;112:423–428.
53.
53. Geerts WH, Jeit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest.2001;119(suppl 1):132S–175S.
54.
54. Andrew M, Marzinotto V, Pencharz P, et al. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. J Pediatr.1995;126:358–363.
55.
55. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist.2004;9:207–216.
56.
56. Jacobs BR. Central venous catheter occlusion and thrombosis. Crit Care Clin.2003;19:1–22.
